Literature DB >> 230519

Dynorphin-(1-13), an extraordinarily potent opioid peptide.

A Goldstein, S Tachibana, L I Lowney, M Hunkapiller, L Hood.   

Abstract

We describe the opioid properties of a tridecapeptide, the sequence of which corresponds to the NH2-terminal sequence of dynorphin, a novel porcine pituitary endorphin. It contains [Leu]enkephalin. In the guinea pig ileum longitudinal muscle preparation it is about 700 times more potent than [Leu]enkephalin. Its effects in this tissue are blocked completely by naloxone, but the apparent affinity of naloxone is 1/13th that for blockade of [Leu]enkephalin or normorphine. In the mouse vas deferens, this peptide is 3 times more potent than [Leu]enkephalin. Well-washed rat brain membranes degrade the peptide rapidly, suggesting the presence of a membrane-bound degradative enzyme. The peptide displays considerable immunoreactivity in assays with antisera that have been used for the immunohistochemical localization of [Leu]enkephalin. The remarkable enhancement of the potency of [Leu]enkephalin by the COOH-terminal extension -Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-OH suggests new interpretations concerning the structure of opiate receptors and the function of the enkephalin pentapeptides.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 230519      PMCID: PMC411929          DOI: 10.1073/pnas.76.12.6666

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  A peptide-like substance from pituitary that acts like morphine. 2. Purification and properties.

Authors:  B M Cox; K E Opheim; H Teschemacher; A Goldstein
Journal:  Life Sci       Date:  1975-06-15       Impact factor: 5.037

2.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

3.  Isolation and amino acid sequence of alpha2-corticotropin-releasing factor (alpha2-CRF) from hog pituitary glands.

Authors:  A V SCHALLY; H S LIPSCOMB; R GUILLEMIN
Journal:  Endocrinology       Date:  1962-07       Impact factor: 4.736

Review 4.  In vitro models in the study of structure-activity relationships of narcotic analgesics.

Authors:  H W Kosterlitz; A A Waterfield
Journal:  Annu Rev Pharmacol       Date:  1975       Impact factor: 13.820

5.  beta-Endorphin: structure-activity relationships in the guinea pig ileum and opiate receptor binding assays.

Authors:  B A Doneen; D Chung; D Yamashiro; P Y Law; H H Loh; C H Li
Journal:  Biochem Biophys Res Commun       Date:  1977-01-24       Impact factor: 3.575

6.  alpha-Neo-endorphin : a "big" Leu-enkephalin with potent opiate activity from porcine hypothalami.

Authors:  K Kangawa; H Matsuo
Journal:  Biochem Biophys Res Commun       Date:  1979-01-15       Impact factor: 3.575

7.  Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antogonist potencies of narcotic analgesics.

Authors:  J Hughes; H W Kosterlitz; F M Leslie
Journal:  Br J Pharmacol       Date:  1975-03       Impact factor: 8.739

8.  (D-Ala2)-Met-enkephalinamide: a potent, long-lasting synthetic pentapeptide analgesic.

Authors:  C B Pert; A Pert; J K Chang; B T Fong
Journal:  Science       Date:  1976-10-15       Impact factor: 47.728

9.  Immunohistochemical localization of enkephalin in rat brain and spinal cord.

Authors:  M Sar; W E Stumpf; R J Miller; K J Chang; P Cuatrecasas
Journal:  J Comp Neurol       Date:  1978-11-01       Impact factor: 3.215

10.  Morphine-tolerant longitudinal muscle strip from guinea-pig ileum.

Authors:  A Goldstein; R Schulz
Journal:  Br J Pharmacol       Date:  1973-08       Impact factor: 8.739

View more
  121 in total

1.  Possible regulatory role of dynorphin A in the urinary bladder.

Authors:  A Berggren; A Dahlström; A Rubenson; U Sillén
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 2.  Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides.

Authors:  V K Shukla; S Lemaire
Journal:  J Psychiatry Neurosci       Date:  1992-09       Impact factor: 6.186

Review 3.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 4.  Dynorphin A analogs for the treatment of chronic neuropathic pain.

Authors:  Sara M Hall; Yeon Sun Lee; Victor J Hruby
Journal:  Future Med Chem       Date:  2016-01-29       Impact factor: 3.808

5.  Biomarker discovery and clinical proteomics.

Authors:  Jerzy Silberring; Pawel Ciborowski
Journal:  Trends Analyt Chem       Date:  2010-02-01       Impact factor: 12.296

6.  Synthesis of 3,6-bis[H-Tyr/H-Dmt-NH(CH2)m,n]-2(1H)pyrazinone derivatives: function of alkyl chain length on opioid activity.

Authors:  Kimitaka Shiotani; Tingyou Li; Anna Miyazaki; Yuko Tsuda; Sharon D Bryant; Akihiro Ambo; Yusuke Sasaki; Lawrence H Lazarus; Yoshio Okada
Journal:  Bioorg Med Chem Lett       Date:  2006-09-01       Impact factor: 2.823

Review 7.  Pathobiology of dynorphins in trauma and disease.

Authors:  Kurt F Hauser; Jane V Aldrich; Kevin J Anderson; Georgy Bakalkin; MacDonald J Christie; Edward D Hall; Pamela E Knapp; Stephen W Scheff; Indrapal N Singh; Bryce Vissel; Amina S Woods; Tatiana Yakovleva; Toni S Shippenberg
Journal:  Front Biosci       Date:  2005-01-01

Review 8.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

9.  Generalization tests with intraventricularly applied pro-enkephalin B-derived peptides in rats trained to discriminate the opioid kappa receptor agonist ethylketocyclazocine.

Authors:  G T Shearman; R Schulz; P W Schiller; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Naloxone treatment attenuates food but not water intake in domestic pigeons.

Authors:  P Deviche; G Schepers
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.